Block Listing Six Monthly Return
30 November 2023
Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).
| Name of applicant: | Futura Medical Plc | |||
| Name of scheme(s): | Unapproved Share Option Scheme Unapproved Share Incentive Scheme EMI Share Option Scheme LTIP Scheme | |||
| Period of return: | From: | 1 June 2023 | To: | 30 November 2023 |
| Balance of unallotted securities under scheme(s) from previous return: | 12,526,721 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | LTIP: 10,590,675 | |||
| Less: Number of securities issued/allotted under scheme(s) during period: | USOS: nil EMI: 756,000 LTIP: 1,578,731
| |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 20,782,665 | |||
| Number and class of securities originally admitted and the date of admission | USOS Total: 3,882,912 814,424 25 May 2011 1,202,280 8 October 2013 1,466,208 25 May 2017 400,000 30 May 2018
USIS Total: 425,000 425,000 30 November 2018
EMI Total: 8,112,088 1,520,576 25 May 2011 1,467,720 8 October 2013 1,893,792 25 May 2017 790,000 30 May 2018 1,340,000 30 November 2018 1,100,000 2 February 2023
LTIP Total: 15,035,617 4,444,942 2 February 2023 10,590,675 3 November 2023 | |||
| |
| |||
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Phil Walker / Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin/ Jonathan Edwards/ Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted two Phase 3 studies using MED3000 in ED; FM57 study which enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura to be granted US marketing authorisation. Both studies demonstrated that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favourable benefit versus risk profile ideally suited for an 'Over the Counter' classification.
Eroxon® is FDA approved in the US, CE marked in?Europe?and UKCA marked in the?UK?as a clinically proven topical treatment for adult men with erectile dysfunction under the brand Eroxon® with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is the agreed brand name in certain regions such as the EU whereas MED3000 continues to be the internal code name used by the Company and also in reference to countries where regulatory approval or commercial distribution agreements have not yet been achieved. www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.